GlassScriptPhysician profile
Fayzan Ahmad
NPI 1376005835
$691.90
in general payments reported to CMS, 2019-2025
16 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $99.17 · 2022: $132 · 2023: $151 · 2024: $59.08 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.99 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.17 | 2021 | |
| Gilead Sciences, INC. | $70.96 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $63.74 | 2024-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $55.30 | 2025 | Ultomiris |
| Pfizer INC. | $55.02 | 2022-2023 | |
| Travere Therapeutics, INC. | $40.07 | 2024-2025 | |
| Abbvie INC. | $36.25 | 2022-2023 | Teflaro |
| Smith+Nephew, INC. | $25.47 | 2024 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.96 | 2023 | |
| Ucb, INC. | $18.26 | 2023 | Briviact |
| Janssen Pharmaceuticals, INC | $15.90 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.86 | 2022 | |
| Abiomed | $14.53 | 2023 | Impella |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $13.90 | 2023 | Xerava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fayzan Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.